FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
CO074 | WHOLE-BLOOD COAGULATION AND PLATELET DYNAMICS IDENTIFY DIFFERENTIAL PROTHROMBOTIC STATES IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK OR TNFⱭ INHIBITORS L. Spiezia, A. Giollo, L. Di Luozzo, M. Salvato, K. Khalid, R. D’Andrea, A. Benetti, C. Samà, R. Ramonda, P. Simioni | Dipartimento di Medicina, Azienda Osp. Università di Padova, Italy
65PDF: 32 -
PO043 | MULTICENTRE REAL‑WORLD EXPERIENCE OF EMICIZUMAB PROPHYLAXIS IN AN ITALIAN COHORT OF 49 CHILDREN WITH SEVERE HEMOPHILIA A - EMIPED STUDY L. Pieri1, B. Pollio2, P. Giordano3, G. Lassandro4, S. Linari1, R. Pasquino1, E. Piellucci1, MC. Di Stefano1, F. Demartis1, R. Fjerza1, G. Castaman1 | 1Center for Bleeding Disorders, Careggi University Hospital, Firenze, Italy; 2Center for Inherited Bleeding and Thrombotic Disorders, Transfusion Medicine, "Regina Margherita" Children Hospital, Torino, Italy; 3Department of Interdisciplinary of Medicine, University of Bari 'Aldo Moro', Bari, Italy; 4General and Specialised Pediatrics Unit, "Giovanni XXIII" Hospital, University of Bari, Bari, Italy
61PDF: 26 -
PO024 | IMPLEMENTATION OF 4PL SIGMOIDAL REGRESSION FOR FACTOR VIII INHIBITOR QUANTIFICATION IN ACQUIRED HEMOPHILIA M. Sebastiani1, M. Bovara2, L. Valdrè3, L. Piscitelli3, R. Mancini2 | 1IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy; 2Laboratorio Unico Metropolitano Ospedale Maggiore, Bologna, Italy; 3Malattie Emorragiche Congenite, Dipartimento Malattie Oncologiche ed Ematologiche IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
60PDF: 22 -
CO-30 | AL AMYLOIDOSIS IN A PATIENT WITH SEVERE HEMOPHILIA A AND INHIBITORS WHO HAD A MONOZYGOTIC TWIN: SAME GENES, DIFFERENT OUTCOMES M. Biglietto1|2, S. Sorella1, S. Ligia1, C. Andriola1, R. Mormile1, E. Baldacci1, A. Chistolini1, C. Santoro1 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Italy; 2Department of Molecular Biology, Sapienza University of Rome, Italy
58PDF: 21 -
PO50 | Treatment with BTK inhibitors in patients affected by chronic lymphocytic leukemia: safety and hemostasis L. Gurgoglione, C.A. Piro, I. Scortechini, I. Battilà, M.C. Merlo, A. R. Scortechini, S. Rupoli, A. Poloni | Hematology Unit, AOU delle Marche-Università Politecnica delle Marche, Italy
535PDF: 22 -
PO28 | CLINICAL IMPLICATIONS OF ANTICOAGULANT DRUG INTERACTIONS WITH TARGETED AND IMMUNE THERAPIES IN ONCOLOGY: A CONTEMPORARY RISK STRATIFICATION FRAMEWORK D. Dhami1, C. Solowiej Singh 1, M. Dhami 2 | 1Abrazo Internal Medicine Residency; 2Eastern Connecticut Hematology Oncology, Norwich, CT, USA
598PDF: 106 -
CO32 | Major surgery in patients with severe hemophilia A without inhibitors receiving prophylaxis with fitusiran E. Zanon, C. Simion, A. Napolitano, L. Spiezia, P. Simioni | Haemophilia Center, First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
582PDF: 33 -
BEST-04 | MAJOR ORTHOPEDIC SURGERY WITH EMICIZUMAB: A SERIES OF 22 PATIENTS (40 PROCEDURES) WITH A MID-TERM FOLLOW-UP G. Daniele1, C. Carulli1, S. Linari2, L. Pieri2, G. Castaman2 | 1Clinica Ortopedica, Azienda Ospedaliero-Universitaria Careggi, Università degli Studi di Firenze, Italy; 2Centro Malattie Emorragiche e della Coagulazione, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy
142PDF: 19 -
CO-59 | CONCIZUMAB IN A YOUNG CHILD WITH SEVERE HEMOPHILIA B WITH INHIBITOR: EFFECTIVE BLEED CONTROL AND SAFE HOME MANAGEMENT T. Martini1, B. Borsellino1|2, B. Pollio1 | 1Hemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy
62PDF: 21 -
PO38 | Rates of hemorrhagic events and hemodialysis circuit thrombosis in patients with end-stage renal disease on hemodialytic treatment receiving a factor-XI inhibitor: a systematic review and meta-analysis D. Santagata, G. Barbui, M.P. Donadini, A. Squizzato | Department of Medicine and Surgery, Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria, Varese and Como, Italy
629PDF: 37 -
BEST-09 | IMMUNOGENIC IMPLICATIONS OF TRANSLATIONAL READTHROUGH MODULATE THE ASSOCIATION OF F8 NONSENSE MUTATIONS WITH INHIBITORS IN HEMOPHILIA A D. Balestra1, M.F. Testa1, M. Pinotti1, A. Branchini1, M.E. Mancuso2, F. Bernardi1 | 1Department of Life Sciences and Biotechnology and LTTA Center, University of Ferrara, Italy; 2IRCCS, Humanitas Research Hospital, Center for Thrombosis and Hemorrhagic diseases, Milano, Italy
145PDF: 24 -
CO-83 | ACQUIRED FACTOR V DEFICIENCY IN A HIGH-THROMBOTIC-RISK PATIENT: DIAGNOSTIC DILEMMA AND SUCCESSFUL MANAGEMENT G. Gazzelli1, L. Banov1, Y. Azzanelli1, C. Vernarecci1, F. Marotta1, F. Giacopelli1, E. Cenni2, V. Agostini2, A.C. Molinari1 | 1IRCCS Istituto Giannina Gaslini, Italy; 2IRCSS AOM S. Martino, Genova, Italy
68PDF: 29 -
PO27 | B-cell lymphoproliferative disorder and acquired coagulopathy: an insidious link C. Caputo, P. Conca, I.L. Calcaterra, E. Cimino, M. Romeo, M. Aversano, E. Franco, C. De Luca, R. Russo, C. Fierarossa, M.N.D. Di Minno, A. Tufano | Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
636PDF: 23 -
PO115 | AL AMYLOIDOSIS IN A PATIENT WITH SEVERE HEMOPHILIA A AND INHIBITORS WHO HAD A MONOZYGOTIC TWIN: SAME GENES, DIFFERENT OUTCOMES M. Biglietto, S. Sorella, S. Ligia, C. Andriola, R. Mormile, E. Baldacci, A. Chistolini, C. Santoro | Sapienza, University of Rome, Italy
60PDF: 24 -
PO076 | ACQUIRED FACTOR V INHIBITOR WITH CONCOMITANT LUPUS ANTICOAGULANT: DIAGNOSTIC PITFALLS AND THERAPEUTIC CHALLENGES G. Gazzelli1, Y. Azzanelli1, C. Vernarecci1, F. Marotta1, F. Giacopelli1, E. Cenni2, V. Agostini2, L. Banov1, AC Molinari1 | 1IRCCS Istituto Giannina Gaslini, Italy; 2IRCSS AOM S. Martino Genova, Italy
80PDF: 32 -
CO-33 | REAL-WORLD EXPERIENCE WITH MARSTACIMAB PROPHYLAXIS IN SEVERE HEMOPHILIA A WITHOUT INHIBITORS AND ADVANCED HEMOPHILIC ARTHROPATHY A. Casson1, I. Ricca1, A. Barchieri1, G. Guido1, M. Tucciarone1, P. Ocello1, C. Francisco2, P. Abrate2, G. Delios1 | 1Centro Malattie Trombotiche ed Emorragiche - SC Servizio Trasfusionale ASL TO4, Ivrea, Torino, Italy; 2SC Farmacia Ospedaliera ASL TO4, Ivrea, Torino, Italy
65PDF: 27 -
Anticoagulation in obese patients: challenges and strategies
2048PDF: 544HTML: 314XML: 200 -
Crosstalk between hemostasis inhibitors and cholesterol biomarkers in multiple sclerosis
2868PDF: 504Supplementary Files: 148 -
CO-60 | A TURNING POINT IN THE MANAGEMENT OF HEMOPHILIA B WITH INHIBITORS: OUTCOMES OF CONCIZUMAB PROPHYLAXIS IN TWO CHILDREN FROM EXPLORER10 G. Quintavalle1, A. Matichecchia1, M.I. Tassoni1, B.M. Roccon1, F. Riccardi1, R.P. Serra2, A. Tiri2, P. Bertolini2, A. Tagliaferri1, A. Coppola1 | 1Regional Hub Center for Hemophilia and Congenital Bleeding Disorders, University Hospital of Parma, Italy; 2Pediatric Hematology-Oncology Unit, University Hospital of Parma, Italy
68PDF: 24 -
Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers
948PDF: 123HTML: 139Supplementary: 79Appendix: 81 -
CO110 | FLOW-BASED WHOLE-BLOOD THROMBUS PROFILING DISCRIMINATES ANTITHROMBOTIC DRUG EFFECTS AND UNCOVERS PLATELET-DEPENDENT COAGULATION DEFECTS AFTER CARDIOPULMONARY BYPASS A. Foladore1, S. Lattanzio1, E. Baryshnikova2, M. Anguissola2, E. Lombardi3, M. Valvasori3, R. Vettori3, F. Agostini3, R. Tassan Toffola4, L. Rota1, M. Ranucci2, M. Mazzucato3 | 1Sedicidodici s.r.l., Pordenone, Italy; 2IRCCS Policlinico San Donato, San Donato Milanese, Italy; 3Centro di Riferimento Oncologico (CRO) IRCCS, Aviano, Italy; 4Azienda Sanitaria Friuli Occidentale, Pordenone, Italy
69PDF: 28 -
The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey
1373PDF: 221HTML: 140Appendix: 121 -
PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience E. Santacroce1,2, C. Santoro1, E. Baldacci1, S. Ligia1, R. Mormile1, M. Biglietto1, M. Totaro1, F. R. Mauro1, M. Breccia1, A. Chistolini1 | 1Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; 2Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy
659PDF: 28 -
PO132 | POST KIDNEY TRANSPLANT PRESENTATION OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA: A CASE OF PRE-EXISTING ADAMTS13 INHIBITORS G. Murante1|2|5, S. Bergonzi1|2|5, M. Capetta1|2|5, F. Valeri1|2, C. Dainese1|2, A. Valpreda4, R. Pastorino1|5, F. Bocchi1|5, L. Biancone3, E. Gallo3, B. Bruno2|5, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases; 2Division of Hematology; 3Nephrology Dialysis and Transplant U; 4Central Lab. Baldi and Riberi, AOU Città della Salute e della Scienza di Torino, Italy; 5Dep. of Molecular Biotechnology and Health Sciences, University of Turin, Italy
55PDF: 29 -
CO-32 | TRAUMA MANAGEMENT IN SEVERE HEMOPHILIA A: A CASE REPORT J. Di Paolo, R. Malizia, M. Luongo, P. Massaro, M. Di Mascio, S. Verna | Immunohematology Service, ASL 02 Abruzzo, Chieti, Italy
49PDF: 20 -
CO36 | Inhibitor titer at diagnosis and clinical course in acquired hemophilia A: a single-center experience C. Simion, B. Stocco, E. Dalla Porta, E. Campello, G. Furlan, L. Spiezia, G. Saggiorato, F. Sartorello, E. Zanon, P. Simioni | Department of Medicine – DIMED, University of Padua, Italy
601PDF: 41 -
The key to fibrinolysis and thrombolysis
1713PDF: 532HTML: 267 -
CO-84 | PARAPROTEIN-DRIVEN ACQUIRED VON WILLEBRAND SYNDROME IN A PATIENT WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND UROTHELIAL CARCINOMA A. Ierardi, A. Strangio, M. Leotta, R.C. Santoro | Hemostasis Unit, AOU Dulbecco, Catanzaro, Italy
49PDF: 24 -
CO073 | THROMBIN GENERATION PROFILE IN ELDERLY PATIENTS WITH ATRIAL FIBRILLATION: IMPACT OF ORAL ANTICOAGULANT TYPE M. Di Gioia1, M. Berteotti1|2, G. Ciarrocca Taranta2, F. Alfano1|2, F. Crudele1, F. Cesari1, A.M. Gori1|2, A. Rogolino1, B. Giusti1|2, R. Marcucci1|2 | 1Atherothrombotic Diseases, Careggi University Hospital, Firenze, Italy; 2Dep. of Experimental and Clinical Medicine, University of Florence, Italy
58PDF: 21 -
CO-27 | INNOVATIVE USE OF EPTACOG BETA TO TREAT ACUTE ELBOW HEMARTHROSIS IN A PEDIATRIC PATIENT WITH HEMOPHILIA B AND A HISTORY OF INHIBITORS, UNDERGOING SECONDARY PROPHYLAXIS WITH CONCIZUMAB L. Laterza1, P. Giordano2, G. Lassandro2 | 1University of Bari "Aldo Moro", Interdisciplinary Department of Medicine, Bari, Italy; 2Pediatric Haemophilia Center-AOUC Pol. Giovanni XXXIII, University of Bari “Aldo Moro”, Bari, Italy
69PDF: 22 -
PO016 | TOLL-LIKE RECEPTOR 4-MEDIATED ENDOTHELIAL DYSFUNCTION VIA NOX2 ACTIVATION IN COVID-19 C. Nocella1|2, V. Castellani2, L. Loffredo1, V. Cammisotto1, S. Bartimoccia1, P. Pignatelli1, R. Carnevale3|4, F. Violi1 | 1Dip di Scienze Mediche e Cardiovascolari, Sapienza Università di Roma, Italy; 2Fondazione Cenci Bolognetti, Istituto Pasteur Italia, Italy; 3IRCCS Neuromed, Italy; 4Dip di Scienze e Biotecnologie Medico-Chirurgiche, Sapienza Università di Roma, Italy
56PDF: 24 -
PO47 | Hemophilia A and antithrombin deficiency: a case of natural hemostatic rebalancing L. Torrieri, S. Ligia, E. Baldacci, R. Mormile, S. Sorella, R. Ciciani, M. Biglietto, N. Zhdanovskaya, A. Delli Paoli, A. Tirnetta, M. Lorenzon, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy
653PDF: 20 -
CO023 | STILL FAR FROM TARGET: REAL-WORLD LDL-CHOLESTEROL CONTROL, THERAPY USE, AND SEX DIFFERENCES IN TUSCANY L. Cosco1, M. Berteotti1, F. Alfano1, F. Profili2, B. Nreu3, G. Casolo4, A. Zuppiroli5, E. Mannucci3, P. Francesconi2, R. Marcucci1 | 1Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy; 2Epidemiology Unit, Regional Health Agency of Tuscany, Firenze, Italy; 3Diabetology Unit, Careggi University Hospital, Firenze, Italy; 4Cardiology Unit, Versilia Hospital, Lido di Camaiore, Italy; 5Former Department of Cardiology, Azienda Sanitaria di Firenze, Firenze, Italy
74PDF: 26 -
PO24 | Emicizumab prophylaxis and bleeding outcomes: a single center clinical experience A. Taglietti1, S. Ligia1, F. Paoletti1, R. Mormile1, E. Baldacci2, A. Chistolini1, C. Santoro1,2 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; 2Hematology, Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy
640PDF: 31 -
PO041 | VARIABLE CLINICAL RESPONSE TO RECOMBINANT PORCINE FVIII IN ACQUIRED HAEMOPHILIA A: A TWO CASE EXPERIENCE WITH LABORATORY SUPPORTED MONITORING AM. Pizzini1, M. Bovara2, M. Sebastiani2, A. Fusco1, C. Fantoni1, M. Silingardi1, R. Mancini2, A. Coppola3 | 1Ambulatorio Emostasi & Trombosi, Dipartimento Medico - Ospedale Maggiore Bologna, Italy; 2Laboratorio Unico Metropolitano - Ospedale Maggiore Bologna, Italy; 3SDD Centro Hub Emofilia e MEC, Azienda Ospedaliero-Universitaria di Parma, Italy
67PDF: 28 -
PO23 | IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA RELATED TO DELAYED IMMUNE CHECKPOINT INHIBITORS TOXICITY: A CASE REPORT E. Galimberti1, F. Schieppati1, C. Ambaglio1, M. Marchetti1, L. Barcella1, A. Falanga1|2 | 1Immunohematology and Transfusion Medicine Unit, ASST Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy
429PDF: 88 -
PO18 | Does muscle mass matter? Appendicular lean mass as a determinant of anti-XA activity in elderly patientes B.M. Zanforlini1, V. Bernardi1, E. Campello2, E.M. Bicego1, C. Curreri1, A. Vaticano1, C. Sartori1, L. Manfron1, A. Perencin1, P. Rollo1, A. Baruffol1, L. Ruoso1, C. Simion2, C. Bulato2, P. Berto2, P. Simioni2, G. Sergi1 | 1Department of Medicine, Geriatrics Section, University of Padova; 2Haemorrhagic and Thrombotic Diseases Unit, Department of Medicine DIMED, Padova University Hospital, Padova, Italy
614PDF: 21 -
PO040 | PHARMACODYNAMIC CHARACTERIZATION OF THROMBIN GENERATION IN SEVERE HEMOPHILIA A PATIENTS ON EMICIZUMAB PROPHYLAXIS: A REAL-WORLD LONGITUDINAL STUDY M. Bergamaschi, A. Pallotta, M. Biglietto, S. Sorella, S. Ligia, E. Baldacci, A. Chistolini, C. Santoro, R. Mormile | Department of translational and precision Medicine, Sapienza, University of Rome, Italy
58PDF: 26 -
CO-20 | REAL-WORLD EXPERIENCE ON THE MANAGEMENT OF MILD HEAD INJURY IN A COHORT OF CHILDREN WITH HEMOPHILIA A WITH AND WITHOUT INHIBITORS TREATED WITH EMICIZUMAB B. Pollio1, B. Borsellino1|2, T. Martini1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy
60PDF: 23 -
CO004 | A NOVEL GENETIC CLASSIFICATION OF INHIBITOR RISK FOR F8 NONSENSE MUTATIONS BASED ON IMMUNOGENIC PROFILING OF RIBOSOMAL READTHROUGH M.F. Testa1, M. Pinotti1, A. Branchini1, M.E. Mancuso2, F. Bernardi1, D. Balestra2 | 1Department of Life Sciences and Biotechnology and LTTA Center, University of Ferrara, Ferrara, Italy; 2IRCCS, Humanitas Research Hospital, Center for Thrombosis and Hemorrhagic diseases, Milano, Italy
161PDF: 30 -
PO67 | Pancreatic cancer in a 71-year-old severe hemophilia A patient with inhibitors and sustained zero bleeding during emicizumab prophylaxis M. Biglietto, A.L. Faccini, S. Sorella, E. Crisanti, M. Antonacci, A. Taglietti, M. Gherardini, A. Tirnetta, S. Ligia, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy
679PDF: 37 -
CO-57 | NXT007 PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS: COMBINED ANALYSIS OF TWO PHASE I/II MULTIPLE-ASCENDING-DOSE STUDIES M.E. Mancuso1|2, M. Shima3, J.M. Staber4, Y.C. Chen5, F.J. López-Jaime6, M.C. Shen7, G. Ventriglia8, M. Takeyama9, C. Schmitt8, Y.S. Park10, A. Kiialainen8, N. Mizuno11, M. Niggli8, T. Miyake11, D. Matino12, T. Saito11, V. Jiménez-Yuste13, R. Kobayashi11, D. Hart14, K. Nogami15 | 1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy; 2Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 3Thrombosis and Hemostasis Research Center, Nara Medical University, Kashihara, Nara, Japan; 4Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, USA; 5Hemophilia Care and Research Center, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan; 6Servicio de Hematología, Hospital Universitario Regional de Málaga / Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain; 7Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan; 8F. Hoffmann-La Roche Ltd, Basel, Switzerland; 9Division of Hemophilia, National Hospital Organization, Osaka National Hospital, Osaka, Japan; 10Department of Pediatrics, Kyung Hee University Hospital at Gangdong, Seoul, South Korea; 11Chugai Pharmaceutical Co., Ltd, Tokyo, Japan; 12McMaster University, Hamilton, Ontario, Canada; 13La Paz University Hospital-IdiPAZ, Autónoma University, Madrid, Spain; 14Roche Products Ltd, Welwyn Garden City, UK; 15Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
73PDF: 25 -
PO045 | FROM PROPHYLAXIS TO ENDOGENOUS CONTROL: A SIX-MONTH REAL-WORLD EXPERIENCE WITH VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY M. Basso1, A. Ferretti1, M. Sacco1, S. Lancellotti1, T. Pirozzi1, L. Di Gennaro1, R. De Cristofaro1|2 | 1Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario Gemelli IRCCS, Italy; 2Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica S. Cuore, Roma, Italy
55PDF: 32 -
PO098 | REAL-WORLD EMERGENCY DEPARTMENT USE OF ANDEXANET ALFA FOR FACTOR XA INHIBITOR REVERSAL: AN ITALIAN COHORT M.P. Donadini1|2, R. Brivio1, S. Bozzato2, L.M. Caiano2, L. Galli2, L. Bertù1, F. Cortellaro2, W. Ageno3 | 1University of Insubria, Varese, Italy; 2ASST Sette Laghi, Varese, Italy; 3University of Padua, Padova, Italy
60PDF: 28 -
CO-55 | DEVELOPMENT OF ENGINEERED LONG-ACTING BYPASSING FX VIA ALBUMIN FUSION FOR HEMOPHILIA WITH INHIBITORS A. Martucci1, R. Tarantino1, K.H. Aaen2, M. Pinotti1, J.T. Andersen2, A. Branchini1 | 1Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy; 2Institute of Clinical Medicine, Department of Pharmacology, University of Oslo, Norway
72PDF: 21 -
PO044 | UPDATING MANAGEMENT OF ACQUIRED HEMOPHILIA A USING EMICIZUMAB: REAL-WORLD OUTCOMES BY A COLLABORATIVE NETWORK OF 3 ITALIAN CENTERS MI. Tassoni1, BM. Roccon1, A. Dalla Salda2, R. Benedetti3, R. Rossi4, C. Cattabiani4, G. Quintavalle1, A. Casali2, D. Imberti3, A. Coppola1 | 1SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Azienda Ospedaliero-Universitaria di Parma, Italy; 2SOC Medicina Interna per acuti ad indirizzo metabolico ed emocoagulativo, Azienda USL IRCCS Reggio Emilia, Italy; 3Centro Emostasi e Trombosi, Medicina Interna, Azienda USL Piacenza, Italy; 4Lab. di Coagulazione, UOC Diagnostica Ematochimica, Azienda Ospedaliero-Universitaria di Parma, Italy
47PDF: 19 -
CO34 | Evaluation of emicizumab concentration and thrombin generation in a cohort of severe hemophilia A patients with and without inhibitor A. Taglietti1, S. Ligia1, F. Paoletti1, R. Mormile1, E. Baldacci2, A. Chistolini1, C. Santoro1,2 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; 2Hematology, Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy
689PDF: 19 -
PO089 | A RISK-ADAPTED, MULTIDISCIPLINARY CONSENSUS FOR ADULT ITP MANAGEMENT: BRIDGING GUIDELINES AND REAL-WORLD PRACTICE A. Votto1, E. Pacini2, G. Giustini3, I. Rina1, S. Galimberti1 | 1Department of Clinical and Experimental Medicine, University of Pisa, Italy; 2Hematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Italy; 3Hematology Unit, AOU Careggi, Firenze, Italy
62PDF: 26 -
PO91 | Disseminated intravascular coagulation with deep vein thrombosis in a frail patient: an extreme manifestation triggered by sepsis during SGLT2i therapy M. Vacca1, M.V. Cherchi1, S. Che1, G.A.M.L. Costanzo2, D. Firinu2, M. Mantega1, S. Del Giacco2 | 1Ospedale Sirai, ASL Sulcis, 2Università degli Studi di Cagliari, Italy
814PDF: 25 -
PO32 | Effect of the sodium-glucose co-transporter-2 (SGLT2) inhibitors on platelet activation and lipid peroxidation: results of a pilot study P.G.M. Simeone1, R. Liani1, M. Alfonsetti1, B. Cancelli1, M. Frezza1, G. Raggiunti1, S. Zeeba2, F. Cipollone1, G. Renda2, F. Santilli1 | 1Department of Medicine and Aging Sciences, Center for Advanced Studies and Technology, University of Chieti; 2Department of Neuroscience, Imaging and Clinical Sciences, G. D’Annunzio University of Chieti-Pescara; 3University Cardiology Division, Heart Department, Policlinico SS Annunziata, Chieti, Italy
623PDF: 23 -
PO116 | MONOCENTRIC EXPERIENCE OF DOACS REVERSAL MANAGEMENT AT L SACCO HOSPITAL, MILAN: A REAL-WORLD RETROSPECTIVE STUDY A. Veltroni, C. Sitzia, O. Di Bartolo, IM Burgo, MC. Carraro, S. Crivelli, C. Masseroni, GB. Inghilleri | Medicina Trasfusionale, Ospedale L. Sacco, Milano, Italy
48PDF: 23 -
PO49 | Use of emicizumab in two patients with acquired hemophilia A: a new therapeutic approach S. Sorella, J. Micozzi, E. Baldacci, M. Biglietto, R. Mormile, A. Chistolini, R. Ciciani, L. Torrieri, N. Zhdanovskaya, M. Lorenzon, A. Delli Paoli, S. Ligia, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy
680PDF: 32 -
CO029 | REAL WORLD EVALUATION OF A NOVEL PATIENT CENTERED OUTCOME INDICATOR TO SUPPORT VALUE BASED HEALTHCARE DECISION-MAKING IN HEMOPHILIA A IN ITALY: THE HEMPROVE NON-INTERVENTIONAL STUDY G. Castaman1, C. Santoro2, E. Ferri Grazzi3, S. Bendinelli4, R. Perrone4, C. Lainez Diaz4, P.A. Cortesi5, M.N.D. Di Minno6 | 1Dep. of Oncology, Centre for Bleeding Disorders and Coagulation, Careggi Univ. Hosp., Firenze, Italy; 2Hematology, Dep. of Translational and Precision Medicine, Sapienza University of Roma, Italy; 3FedEmo, Milano, Italy; 4Roche S.p.A. Italy, Monza, Italy; 5CESP, Univ. of Milano-Bicocca, Monza, Italy; 6Dep. of Clinical Medicine and Surgery, Regional Reference Center for Coagulation Disorders, Federico II Univ., Napoli, Italy
81PDF: 32 -
PO44 | PREDICTORS OF ONE-YEAR MORTALITY IN NEWLY DIAGNOSED METASTATIC BREAST CANCER: THE PROGNOSTIC ROLE OF HEMOSTATIC BIOMARKERS AND EARLY THROMBOEMBOLISM M. Marchetti1|2|3, P. Gomez-Rosas1|4|5, S. Bolognini1, C. Ticozzi1, D. Romeo1, F. Schieppati1|3, L. Barcella1|3, F. Petrelli6, A. D'Alessio7, R. Labianca7, A. Falanga1|2|3 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; 3ERN EuroBloodNet; 4Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands; 5Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; 6Oncology Unit, Hospital Treviglio-Caravaggio, Treviglio, Italy; 7Fondazione ARTET Onlus, Bergamo, Italy; *On behalf of the Hypercan Investigators
491PDF: 111 -
CO33 | Acquired hemophilia A in Liguria, Italy: what six years of data reveal C. Vernarecci1, A. C. Molinari1, P. Ballarino2, M. Caiti2, E. Cenni2, P. Moscatelli2, L. Banov1 | 1IRCCS Istituto Giannina Gaslini, Genova; 2IRCCS Policlinico San Martino, Genova, Italy
628PDF: 41 -
PO079 | PERIOPERATIVE MANAGEMENT OF MILD-TO-MODERATE HEMOPHILIA: A COMPARATIVE STUDY OF EXTENDED HALF-LIFE VERSUS STANDARD HALF-LIFE CONCENTRATES ON CLINICAL OUTCOMES AND FACTOR CONSUMPTION M. Capetta1|2|3, F. Valeri1|2, C. Dainese1|2, S. Bergonzi1|2|3, G. Murante1|2|3, A. Valpreda4, R. Pastorino1|3, F. Bocchi1|3, B. Bruno2|3, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Torino, Italy; 2Division of Hematology, AOU Città della Salute e della Scienza, Università di Torino, Torino, Italy; 3Department of Molecular Biotechnology and Health Sciences, University of Turin, Torino, Italy; 4Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Università di Torino, Torino, Italy
60PDF: 25 -
CO-40 | ONE-STAGE ASSAYS VS. CHROMOGENIC ASSAYS IN rpFVIII: STILL A DISCREPANCY? L. Banov, G. Gazzelli, Y. Azzanelli, C. Vernarecci, F. Marotta, F. Giacopelli, F. Tappino, A.C. Molinari | IRCCS Istituto Giannina Gaslini, Genova, Italy
63PDF: 22 -
PO86 | Emicizumab in patients with moderate hemophilia A and severe bleeding phenotype: single-center real-world experience A.L. Faccini, M. Biglietto, S. Sorella, E. Crisanti, M. Antonacci, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro, S. Ligia | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy
767PDF: 35 -
BEST-05 | LONG-TERM EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A: REAL-WORLD EXPERIENCE ACROSS ALL AGES A. Colombo1, I. Quaglia1, M.R. Fasulo1, C. Lodigiani1, M.E. Mancuso1|2 | 1Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy
154PDF: 23 -
CO-62 | ACCESS TO ULTRA-LONG HALF-LIFE FACTOR VIII AS THE DEFINITIVE MOTIVATION FOR IMMUNE TOLERANCE INDUCTION IN THE ERA OF NON-REPLACEMENT THERAPIES B. Borsellino1, T. Martini1, I. Ricca2, C. Linari3, B. Pollio1 | 1Paediatric Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital "Città della Salute e della Scienza", Torino, Italy; 2Transfusion Medicine, Ivrea Hospital, Ivrea, Italy; 3Department of Laboratory Medicine, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin, Italy
61PDF: 22 -
PO042 | ACQUIRED HEMOPHILIA A AND ANTIPHOSPHOLIPID SYNDROME: CONCURRENCY OR OVERLAPPING? E. Galimberti1, C. Ambaglio1, T. Zollner1, F. Schieppati1|2, O.C. Cretu1, F. Zunino1, V. Brusegan1, M. Marchetti1|2, A. Falanga1|2, L. Barcella1 | 1Immunohematology and Transfusion Medicine, Department of Transfusion Medicine and Hematology, ERN-EuroBloodNet - European Reference Network in Rare Hematological Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy
56PDF: 28 -
CO-24 | BALANCING BLEEDING AND THROMBOSIS: SAFETY OF LOW-MOLECULAR-WEIGHT HEPARIN THROMBOPROPHYLAXIS IN PATIENTS WITH HEMOPHILIA UNDERGOING MAJOR SURGERY S. Bergonzi1|2|3, G. Murante1|2|3, M. Capetta1|2|3, F. Valeri1|2, C. Dainese1|2, A. Valpreda3|4, R. Pastorino3|4, F. Bocchi3|4, B. Bruno2|3, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Torino, Italy; 2Division of Hematology, AOU Città della Salute e della Scienza, University of Turin, Italy; 3Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 4Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, University of Turin, Italy
63PDF: 26 -
PO150 | FACTOR XII DEFICIENCY IN THE SETTING OF RECURRENT THROMBOSIS AND EXTENDED VENOUS OBSTRUCTION: A CASE ANALYSIS L. Leoni1, G. Pata1, A. Domenighini1, L. Crippa2, T. D'aliberti1, G. Galimberti1, F. Paciullo1, P. Rovere Querini1 | 1Internal Medicine Unit; 2Coagulation Service Thrombosis Research Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy
43PDF: 24 -
PO077 | BALANCING BLEEDING AND THROMBOSIS: SAFETY OF LOW-MOLECULAR-WEIGHT HEPARIN THROMBOPROPHYLAXIS IN PATIENTS WITH HEMOPHILIA UNDERGOING MAJOR SURGERY S. Bergonzi1|2|3, G. Murante1|2|3, M. Capetta1|2|3, F. Valeri1|2, C. Dainese1|2, A. Valpreda3|4, R. Pastorino3|4, F. Bocchi3|4, B. Bruno2|3, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Turin, Italy; 2Division of Hematology, AOU Città della Salute e della Scienza, Università di Torino, Italy; 3Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 4Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Università di Torino, Italy
49PDF: 26 -
CO-36 | PLATELETS MATTER: THROMBIN GENERATION IN PLATELET‐RICH-PLASMA VS. PLATELET‐POOR‐PLASMA UNDER NON-REPLACEMENT THERAPIES IN HEMOPHILIA F. Bocchi1|2, R. Pastorino1|2, G. Murante1|2|3, S. Bergonzi1|2|3, M. Capetta1|2|3, F. Valeri2|3, C. Dainese2|3, A. Valpreda4, B. Bruno1|3, A. Borchiellini2|3 | 1Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 2Regional Centre for Thrombotic and Hemorrhagic Diseases, AOU Città della salute e della Scienza di Torino, Italy; 3Division of Hematology, AOU Città della Salute e della Scienza, University of Turin, Italy; 4Central Lab Baldi and Riberi, AOU Città della salute e della Scienza di Torino, Italy
62PDF: 21 -
PO69 | Whole blood thrombin generation hypercoagulable profile in a patient with hemolytic crisis due to paroxysmal nocturnal hemoglobinuria: a case report A. Napolitano, L. Spiezia, C. Bulato, E. Campello, P. Simioni | First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
718PDF: 25 -
PO015 | OSA VS. CHA FOR RPFVIII MEASURE: STILL AN ISSUE? G. Gazzelli, Y. Azzanelli, C. Vernarecci, F. Marotta, F. Giacopelli, B. Tappino, L. Banov, A.C. Molinari | IRCCS Istituto Giannina Gaslini Genova, Italy
58PDF: 23 -
PO114 | A CASE OF ACQUIRED HEMOPHILIA AFTER TAVI AND CORONARY ANGIOPLASTY IN PATIENT WITH ATRIAL FIBRILLATION AND MULTIPLES CARDIOVASCULAR RISK FACTORS – THE ART AND SCIENCE OF THERAPEUTIC CONFLICT M.M. Poggi1, C. Tamburini2, M. Littera2, M. Mazzetti2 | 1SOC Medicina 1, Nuovo Ospedale Prato, Prato, Italy; 2SOD Medicina Interna Interdisciplinare, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
65PDF: 28 -
CO-23 | PERIOPERATIVE MANAGEMENT OF MILD-TO-MODERATE HEMOPHILIA: A COMPARATIVE STUDY OF EXTENDED HALF-LIFE VERSUS STANDARD HALF-LIFE CONCENTRATES ON CLINICAL OUTCOMES AND FACTOR CONSUMPTION M. Capetta1|2|3, F. Valeri1|2, C. Dainese1|2, S. Bergonzi1|2|3, G. Murante1|2|3, A. Valpreda4, R. Pastorino1|3, F. Bocchi1|3, B. Bruno2|3, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Torino, Italy; 2Division of Hematology, AOU Città della Salute e della Scienza, University of Turin, Italy; 3Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 4Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, University of Turin, Italy
66PDF: 21 -
PO46 | Intravitreal treatment with faricimab in patients with age-related macular degeneration M. Alfonsetti1, R. Liani1, P.G.M. Simeone1, M. Frezza1, A. Ricci3, S. Lattanzio1, R. D’Aloisio2, L. Toto2, F. Santilli1 | 1Department of Medicine and Aging, Center for Advanced Studies and Technology “CAST”; 2Ophthalmology Clinic, Department of Medicine and Aging; 3Department of Pharmacy, University “G. d’Annunzio” of Chieti Pescara, Chieti, Italy
497PDF: 22 -
PO145 | KINETIC ASSESSMENT OF PLATELET REACTIVITY DURING DUAL ANTIPLATELET THERAPY IN ACUTE CORONARY SYNDROMES: PRELIMINARY RESULTS FROM AN ONGOING STUDY B. Di Marco1|2, R. Liani1, F. D’Ambrosio1|2, M. Alfonsetti1, P.G. Simeone1, M. Frezza1, S. Porro1, M. Brambilla3, P. Lanuti1, M. Camera3, F. Santilli1 | 1Department of Medicine and Aging Sciences, Center for Advanced Studies and Technology (CAST), University of Chieti, Chieti, Italy; 2ASL 2 Abruzzo, SS. Annunziata Hospital, Chieti, Italy; 3Unit of Cell and Molecular Biology in Cardiovascular Diseases, Centro Cardiologico Monzino IRCCS, Milano, Italy
60PDF: 22 -
CO005 | HEPATIC ENDOTHELIUM AS A SAFE AND DURABLE TARGET FOR LENTIVIRAL GENE THERAPY OF HEMOPHILIA A E. Borroni, F. Antony, S. Merlin, V. Kalandadze, C. Borsotti, A. Follenzi | Università del Piemonte Orientale, Novara, Italy
170PDF: 26 -
CO31 | Immune system profiling in FVIII-treated and emicizumab-treated pediatric HA patients A. Cottonaro1, S. Akula1, B. Pollio2, I. Ricca2, T. Martini2, J. Agnelli Giacchello3, P. Sciancalepore3, R. Santi3, A. Follenzi1,3, S. Merlin1 | 1Università del Piemonte Orientale, Health Sciences, Novara; 2A.O. Città della Salute e della Scienza, SIMT Immunohematology and Transfusion Medicine Service, Diagnostic Department, Torino; 3Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
658PDF: 24 -
PO68 | Whole blood hypercoagulable profiles in a patient with markedly elevated lipoprotein(A) plasma levels and thrombotic complications: a case report C. Portinari, M. Biolo, A. Napolitano, L. Spiezia, A. Colpo, S. Zambon, A. Zambon, P. Simioni | Department of Medicine, Padova University Hospital, Padova, Italy
658PDF: 32 -
BEST-01 | IDENTIFICATION OF NOVEL HYPERACTIVE rFVIIa BYPASSING MOLECULES INFERRED BY ANCESTRAL SEQUENCE RECONSTRUCTION APPROACH M.F. Testa, I. Passerini, P. Santos, A. Benazzo, S. Ghirotto, F. Bernardi, A. Branchini, M. Pinotti, D. Balestra | Dep. of LSB, University of Ferrara, Italy
175PDF: 32 -
PO112 | REFRAMING THE ENIGMA: ACQUIRED HEMOPHILIA A AS A HARBINGER OF HHV-8–ASSOCIATED MULTICENTRIC CASTLEMAN DISEASE M. Palladino1, G. Gammaitoni1, C. Santoro2, M. Muscaritoli1 | 1Medicina Interna e Nutrizione Clinica-Dip. Medicina Traslazionale e di Precisione; 2Ematologia- Dip. Medicina Traslazionale e di Precisione, Umberto I Roma, Italy
48PDF: 29 -
PO05 | DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF NOVEL IMATINIB AND NILOTINIB ANALOGUES EXPRESSING ENHANCED ANTIPLATELET AND ANTICANCER ACTIVITIES D. Pantazi1, L. Pechlivani1, A. Kosma1, K. Lalechou1, M.G. Siskos2, D. Alivertis3, A.D. Tselepis1 | 1Atherothrombosis Research Centre, Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Greece; 2Laboratory of Organic Chemistry, Department of Chemistry, University of Ioannina, Greece; 3Department of Biological Applications and Technology, University of Ioannina, Greece
570PDF: 108 -
CO27 | Intracerebral hemorrhage in hemophilia A and B: a 10-year prospective multicenter study in Italy (2012–2022) E. Zanon1, A. Napolitano1, A. Porreca2, F. Demartis3, A. Coppola4, C. Santoro5, I. Cantori6, A. C. Molinari7, C. Biasioli8, M. Luciani9, G. Sottilotta10, B. Pollio11, A. Borchiellini12, A. Tosetto13, P. Flora14, P. Simioni1 | 1Haemophilia Center, First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua; 2Department of Human Sciences and Promotion of the Quality of Life, Unit of Clinical and Molecular Epidemiology IRCCS San Raffaele Roma Open University, Roma; Unit of Clinical and Molecular Epidemiology IRCCS San Raffaele, Roma; 3Centre for Bleeding Disorders, Careggi University Hospital of Firenze; 4Azienda Ospedaliero Universitaria di Parma; 5Hematology Division, Umberto I University Hospital of Roma; 6Haemophilia Center, Department of Transfusion Medicine, Hospital of Macerata; 7IRCCS Istituto Giannina Gaslini, Genova; 8Haemophilia and Transfusion Centre, Bufalini Hospital, Cesena; 9Children’s Hospital Bambino Gesù, Roma; 10Haemophilia Center, Department of Onco-Hematology and Radioterapy, Hospital of Reggio Calabria; 11Haemophilia Pediatric Center, Transfusion Medicine, City of Health and Science of Turin; 12City of Health and Science of Turin; 13Hemorrhagic and Thrombotic Diseases Unit, S. Bortolo Hospital of Vicenza; 14RCCS Foundation Ca’ Granda Maggiore Policlinico Hospital, Milan, Italy
712PDF: 42 -
PO075 | HEMOSTATIC AND CARDIOVASCULAR PROFILES IN HEMOPHILIA PATIENTS WITH AND WITHOUT ATHEROSCLEROSIS A. Napolitano, E. Zanon, L. Spiezia, G. Camporese, P. Scarinzi, F. Ahmad, G. Saggiorato, C. Bulato, F. Sartorello, S. Toffanin, A. Montagna, V. Azzaro, C. Simion, E. Campello, P. Simioni | Department of Medicine, University of Padova, Italy
45PDF: 23 -
CO077 | PLATELET MIR-144-5P REGULATES COX-1/2 EXPRESSION AND MODULATES ASPIRIN RESPONSE IN PATIENTS WITH CARDIOMETABOLIC RISK P. Simeone1, R. Liani1, V. Abbonante2, M. Alfonsetti1, M. Frezza1, P. Lanuti1, A. Recchiuti3, A. Balduini2, F. Santilli1 | 1Department of Medicine and Aging, and Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy; 2Department of Molecular Medicine, University of Pavia, Pavia, Italy; 3Department of Medical, Oral, and Biotechnological Science, Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy
59PDF: 26 -
PO14 | Searching for safer rescue immunosuppressive therapy protocols in acquired hemophilia A: two case reports G. Quintavalle1, I.M. Tassoni1, B.M. Roccon1, G. Lucchini2, F. Magalini2, M. Zardo2, R. Rossi3, C. Cattabiani3, A. Tagliaferri1, A. Coppola1 | 1SSD Centro HUB Emofilia e MEC; 2UOS Medicina Interna e Reumatologia; 3UO Diagnostica Ematochimica, Azienda Ospedaliero Universitaria, Parma, Italy
568PDF: 35 -
PO108 | DIRECT ORAL ANTICOAGULANTS IN PATIENTS WITH VENOUS THROMBOEMBOLISM RECEIVING LONG-TERM IMMUNOSUPPRESSIVE THERAPY AFTER LIVER AND KIDNEY TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE U. Mazzarelli1, L. Agrelli1, A. Cirillo1, C. Crescenzo2, M. Triggiani1, A. Guida3 | 1Dipartimento di Medicina Interna, Università degli studi di Salerno, Italy; 2UOC Nefrologia e Trapianti di rene; 3Centro per le malattie emorragiche congenite e malattie trombotiche, AOU San Giovanni di Dio e Ruggi d'Aragona Salerno, Italy
71PDF: 30 -
PO035 | ASSESSMENT OF HIGH-ON-TREATMENT PLATELET REACTIVITY IN PATIENTS ON DUAL ANTIPLATELET THERAPY USING THE FULLY AUTOMATED COAGULATION ANALYZER SYSMEX CN-6500: A COMPARATIVE STUDY WITH THREE POINT-OF-CARE TESTS E. Falcinelli1, L. Bury1, E. Giglio1, A.M. Mezzasoma1, V. Fazzi1, M. del Pinto2, M. Lenti3, A. Rechner2, P. Gresele1 | 1Dept of Medicine and Surgery, Section of Internal and Cardiovascular Medicine; 2Dept. of Cardiology; 3Dept of Vascular Surgery, University of Perugia, Italy; 4Sysmex Europe
62PDF: 24 -
CO-19 | A CASE OF LOSS OF EFFICACY OF EMICIZUMAB AFTER 6 YEARS OF REGULAR USE M.R. Fasulo1, I. Quaglia1, A. Colombo1, C. Lodigiani1, M.E. Mancuso1|2 | 1Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy
66PDF: 23 -
PO44 | Emicizumab in acquired haemophilia A M. Leotta, A. Strangio, A. Ierardi, S. Prejanò, R C. Santoro | Hemostasis and Thrombosis Unit, Department Hemato-Oncology, Azienda Ospedaliero-Universitaria Renato; Dulbecco, Catanzaro, Italy
639PDF: 28 -
PO131 | BEYOND THE INHIBITOR TITER: THE IMPORTANCE OF EARLY COMBINED IMMUNOSUPPRESSIVE THERAPY IN THE MANAGEMENT OF ACQUIRED HEMOPHILIA A M. Luongo1, P. Massaro1, M. Di Mascio1, P.G. Simeone2, F. Santilli2, S. Verna1 | 1Immunohematology Service, Asl 02 Abruzzo, Chieti, Italy; 2Department of Medicine and Aging Sciences, and Center for Advanced Studies and Technology, “G. d’Annunzio” University of Chieti–Pescara, Italy
55PDF: 28 -
CO-86 | A RARE CASE OF ACQUIRED HEMOPHILIA A ASSOCIATED WITH MYELOPROLIFERATIVE NEOPLASM A. Ierardi, A. Strangio, M. Leotta, R.C. Santoro | Hemophilia, Hemostasis and Thrombosis Unit, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy
58PDF: 26 -
OC09 | BLEEDING RISK ASSOCIATED WITH FACTOR XI MONOCLONAL ANTIBODIES IN COMBINATION WITH ASPIRIN IN HEALTHY VOLUNTEERS AND ORTHOPEDIC SURGERY PATIENTS: ANALYSIS FROM RECENT PHASE 1 AND PHASE 2 STUDIES A.P. Kithcart1, M.E. Burczynski1, P. Banerjee1, M. Onisko1, Y. Wang1, K. Mohammadi1, D. Li1, S. Li1, J. Ackroyd2, B.A. Olenchock1, D.E. Gutstein1, J. I. Weitz3 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Clinical Research, Fortrea Clinical Research Unit Ltd, Leeds, UK; 3McMaster University, Hamilton, ON, Canada
466PDF: 123 -
CO18 | Relationship between gut permeability and PCSK9 in heterozygous familial hypercholesterolemia V. Castellani1, V. Cammisotto2, F. Baratta2, S. Bartimoccia3, C. Nocella2, L. D’erasmo1, N. Cocomello2, C. Barale4, R. Scicali5, I. Russo4, F. Purrello5, R. Carnevale3, F. Violi2, M. Arca1, P. Pignatelli2 | 1Department of Translational and Precision Medicine, Sapienza University of Roma; 2Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Roma; 3Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Roma; 4Department of Clinical and Biological Sciences, University of Turin; 5Department of Clinical and Experimental Medicine, Internal Medicine, University of Catania, Italy
619PDF: 23 -
CO-31 | WHEN NECK PAIN HIDES A SPINAL BLEED: ANTERIOR CERVICAL EPIDURAL HEMATOMA IN A CHILD WITH HEMOPHILIA B E. Dalla Porta, C. Simion, E. Zanon, B. Stocco, L. Spiezia, P. Simioni | Hemophilia Center, University Hospital of Padua, Italy
58PDF: 21
